|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:conditionStudied
|
severe aortic stenosis
|
|
gptkbp:contrastsWith
|
surgical aortic valve replacement
|
|
gptkbp:enrollment
|
over 2000 patients
|
|
gptkbp:fullName
|
Placement of Aortic Transcatheter Valves (PARTNER) 2 trial
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PARTNER 2 trial
|
|
gptkbp:location
|
gptkb:Canada
gptkb:Europe
gptkb:United_States
|
|
gptkbp:number
|
NCT01314313
|
|
gptkbp:period
|
Phase 3
|
|
gptkbp:population
|
intermediate-risk patients with severe aortic stenosis
|
|
gptkbp:principalInvestigator
|
gptkb:Craig_R._Smith
|
|
gptkbp:publicationYear
|
2016
|
|
gptkbp:publishedIn
|
gptkb:New_England_Journal_of_Medicine
|
|
gptkbp:result
|
TAVR had higher rates of paravalvular leak
TAVR had lower rates of major bleeding
death or disabling stroke at 2 years
TAVR was non-inferior to surgery for primary endpoint
|
|
gptkbp:sponsor
|
gptkb:Edwards_Lifesciences
|
|
gptkbp:startYear
|
2011
|
|
gptkbp:studiedIntervention
|
transcatheter aortic valve replacement
|
|
gptkbp:bfsParent
|
gptkb:PARTNER_trial
|
|
gptkbp:bfsLayer
|
8
|